ClinicalTrials.govpublic full text
TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
antibody-mediated rejection, kidney transplant, chronic rejection, graft function, donor specific antibodies (dsa), transplant-specific well-being, adherence, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1072407
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.